Corifollitropin alfa N02 versus recombinant FSH for ovarian stimulation: a phase 3 trial and safety study in Chinese women.

Reprod Biomed OnlineJun 11, 2026 (epub)
Clinical ResearchObstetrics & Gynecology

Tingting Li, Xiujuan Chen, Yingpu Sun et al.

✦ AI-curated · Sources linked

In 30 seconds

This phase 3 randomized controlled trial evaluated the efficacy and safety of corifollitropin alfa N02 compared to daily recombinant FSH (rFSH) for ovarian stimulation in 474 Chinese women aged 20-39 with normal ovarian reserve. The corifollitropin alfa N02 group retrieved a mean of 12.1 oocytes, demonstrating non-inferiority to the 10.9 oocytes retrieved in the rFSH group.

Key findings

  • Mean oocytes retrieved: 12.1 for corifollitropin alfa N02 vs 10.9 for daily rFSH.
  • Clinical pregnancy rate: 46.3% in corifollitropin alfa N02 group vs 51.1% in rFSH group.
  • Ovarian hyperstimulation syndrome occurred in 3.8% of corifollitropin alfa N02 group vs 2.5% in rFSH group.
  • Birth defect rate: 7.6% for corifollitropin alfa N02 vs 12.0% for daily rFSH.

Why it matters

The findings suggest that corifollitropin alfa N02 provides a viable alternative to daily rFSH for ovarian stimulation, potentially simplifying treatment protocols while maintaining similar efficacy and safety profiles.

Source

PubMed · PMID 42462332

Published in Reprod Biomed Online. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.